Entering text into the input field will update the search result below

Fortress Biotech Non-GAAP EPS of -$0.10 misses by $0.03, revenue of $18.89M misses by $4.29M

Aug. 11, 2022 4:59 PM ETFortress Biotech, Inc. (FBIO) StockBy: Niloofer Shaikh, SA News Editor2 Comments
  • Fortress Biotech press release (NASDAQ:FBIO): Q2 Non-GAAP EPS of -$0.10 misses by $0.03.
  • Revenue of $18.89M (+5.9% Y/Y) misses by $4.29M.
  • "In 2023, we expect to enroll the first patient in a pivotal multicenter Phase 2 clinical trial under Mustang Bio’s Investigational New Product Drug Application (“IND”) to evaluate MB-107, a lentiviral gene therapy for the treatment of infants under the age of two with XSCID."

Recommended For You

About FBIO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
FBIO--
Fortress Biotech, Inc.